Article
Hematology
Friederike Wiebe, Stefan Handtke, Jan Wesche, Annabel Schnarre, Raghavendra Palankar, Martina Wolff, Kristin Jahn, Franziska Voss, Sabrina Weismueller, Joerg Schuettrumpf, Andreas Greinacher, Sven Hammerschmidt
Summary: Platelets play a crucial role in the development of respiratory distress, and the toxin pneumolysin produced by Streptococcus pneumoniae can impair platelet function. This study shows that both polyvalent immunoglobulin preparations are effective in inhibiting pneumolysin-induced platelet destruction and maintaining platelet function.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Food Science & Technology
Jasmin Bazant, Benjamin Ott, Martina Hudel, Torsten Hain, Rudolf Lucas, Mobarak Abu Mraheil
Summary: H2O2 negatively affects the activity and release of PLY. Decreased H2O2 production leads to a decline in PLY release, possibly due to the upregulation of certain genes.
Article
Health Care Sciences & Services
Christopher C. Blyth, Kathryn J. Britton, Cattram D. Nguyen, Joycelyn Sapura, John Kave, Birunu Nivio, Jocelyn Chan, Catherine Satzke, Rebecca Ford, Wendy Kirarock, Deborah Lehmann, William Pomat, Fiona M. Russell
Summary: This study evaluates the effectiveness of the 13-valent pneumococcal conjugate vaccine (13vPCV) in reducing hypoxic pneumonia and hospitalization in children in Eastern Highlands Province, Papua New Guinea (PNG).
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2022)
Article
Immunology
Greiciely O. Andre, Mayara T. Borges, Lucas Assoni, Lucio F. C. Ferraz, Piplani Sakshi, Penelope Adamson, David L. Gordon, Abiodun D. Ogunniyi, Henrietta Venter, Thiago R. Converso, Michelle Darrieux
Summary: The implementation of polysaccharide-based vaccines reduced the incidence of pneumococcal diseases, but concerns remain over serotype replacement and antibiotic resistance. Novel vaccine strategies utilizing conserved pneumococcal antigens like PhtD show promise in providing serotype-independent protection in mouse models.
Review
Immunology
Hisanori Domon, Yutaka Terao
Summary: Streptococcus pneumoniae is a major human pathogen that causes diseases like bacterial pneumonia, otitis media, meningitis, and septicemia. Research has primarily focused on the bacterium's virulence factors, but recent evidence highlights the importance of understanding host factors and interactions in the pathogenesis of pneumococcal diseases. Neutrophil accumulation and elastase play crucial roles in the progression of pneumococcal pneumonia.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Review
Immunology
Javid Aceil, Fikri Y. Avci
Summary: This review provides an overview of multiple classes of conserved surface proteins as vaccine targets for Streptococcus pneumoniae, discussing their contribution to the virulence of pneumococcal disease and their potential as vaccine targets.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Immunology
Joseph A. Lewnard, Noga Givon-Lavi, Ron Dagan
Summary: The study analyzed the effectiveness of PCV in protecting children against pneumonia caused by different vaccine-targeted pneumococcal serotypes in southern Israel. The results showed that PCV could effectively reduce carriage of vaccine-serotype pneumococci and decrease the risk of disease progression.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Runbao Du, Tian Wang, Hongfa Lv, Yinuo Zou, Xiaoning Hou, Nana Hou, Peng Zhang, Hongen Li, Gefu Chi
Summary: This study explored the anti-infective effect of shionone, a tetracyclic triterpenoid compound, against Streptococcus pneumoniae. The results showed that shionone exhibited excellent hemolytic inhibitory activity and disrupted the oligomerization of pneumolysin (PLY). Molecular docking analysis indicated that shionone targeted specific amino acid sites to reduce S. pneumoniae pathogenicity. Furthermore, shionone demonstrated protective effects in a mouse pneumonia model by alleviating lung injury and reducing bacterial colonization. These findings suggest that shionone has the potential to combat S. pneumoniae infection.
Article
Immunology
Rui Ding, Yan Zhang, Xiangzhu Xu, Yunfeng Hou, Jing Nie, Xuming Deng, Jiazhang Qiu, Qianghua Lv
Summary: This study analyzed the inhibitory effect of the natural compound hederagenin on Streptococcus pneumoniae and found that it has great potential as a treatment strategy for pneumococcal diseases.
MICROBES AND INFECTION
(2022)
Article
Immunology
Maria Morales-Suarez-Varela, Diana Toledo, Maria Amelia Fernandez-Sierra, Maria Liebana, Gerardo Rubiera, Gema Navarro, Concepcion Prados, Judith Chamarro, Isabel Peraita-Costa, Angela Dominguez
Summary: This retrospective cohort study found that individuals who were vaccinated against pneumococcal disease had a lower risk of developing SARS-CoV-2 pneumonia compared to those who were not vaccinated. The study also identified certain high-risk groups for developing SARS-CoV-2 pneumonia, such as individuals with obesity, diabetes, and respiratory diseases, who could potentially benefit from vaccination and monitoring.
Article
Immunology
Jimstan Periselneris, Carolin T. Turner, Giuseppe Ercoli, Gabriella Szylar, Caroline M. Weight, Teresa Thurston, Matthew Whelan, Gillian Tomlinson, Mahdad Noursadeghi, Jeremy Brown
Summary: The virulence factor Pneumolysin (Ply) of Streptococcus pneumoniae has contradictory effects on the host inflammatory response to infection. This study found that Ply suppressed the macrophage inflammatory response to S. pneumoniae, possibly mediated through SOCS1, and was associated with improved immune evasion during early lung infection.
Review
Immunology
Sha Li, Hangeri Liang, Shui-Hao Zhao, Xiao-Yan Yang, Zhong Guo
Summary: This review provides an overview of the advancements made in the development of protein-based pneumococcal vaccines. The key protein vaccine candidates and their vaccination results in animal studies are discussed, as well as the challenges and future directions in protein-based pneumococcal vaccine.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Yali Cui, Chenglin Miao, Wen Chen, Wenling Shang, Qianqian Qi, Wei Zhou, Xia Wang, Yingying Li, Ziyi Yan, Yongmei Jiang
Summary: This study designed a novel fusion protein, NanAT1-TufT1-PlyD4, to combat pneumococcal infections. The protein exhibited stability and immunogenicity, and significantly reduced the damage caused by pneumococcal infection in the lungs.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Microbiology
Hisanori Domon, Toshihito Isono, Takumi Hiyoshi, Hikaru Tamura, Karin Sasagawa, Tomoki Maekawa, Satoru Hirayama, Katsunori Yanagihara, Yutaka Terao
Summary: Macrolides such as clarithromycin have been shown to inhibit pneumolysin release in macrolide-resistant Streptococcus pneumoniae (MRSP). Clarithromycin downregulates the gene encoding pneumolysin, decreases pneumococcal growth, and improves lung injury in a mouse model of pneumonia. Targeting pneumolysin may be a promising strategy for treating pneumococcal pneumonia.
MICROBIOLOGY SPECTRUM
(2021)
Article
Immunology
Carlos A. Sanchez, Michelle Lozada-Urbano, Pablo Best-Bandenay
Summary: This study analyzed the impact of conjugated pneumococcal vaccines (PCVs) on pneumonia mortality among young children in Peru. The results showed a decrease in pneumonia mortality rates for children between 1-4 years of age and infants after the introduction of PCVs. There was an inflection point in 2013 for infants, but not for toddlers/preschoolers, suggesting a difference in the impact of PCVs for each age group.